We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.00 | 0.19% | 1,586.50 | 1,586.50 | 1,587.00 | 1,587.50 | 1,575.00 | 1,579.50 | 777,732 | 12:10:16 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.21 | 65.11B |
From Apr 2019 to Apr 2024
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) said Monday that a phase 3 study of its cancer drug niraparib, which is marketed under the name Zejula, yielded positive results.
The drug demonstrated a statistically-meaningful improvement in survival without disease progression in women with ovarian cancer, regardless of their biomarker status, the British pharmaceutical company said.
Safety results were consistent with previous clinical trials. The medication was being administered as a first-line maintenance treatment following platinum based chemotherapy.
GlaxoSmithKline said full results from the study, called Prima, will be made public at an upcoming scientific meeting.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
July 15, 2019 02:28 ET (06:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
